Table 1.
Demographic, clinical, and laboratory characteristics of psoriatic patients with and without non-alcoholic fatty liver disease (NAFLD).
| Variable | No NAFLD (n = 124) |
NAFLD (n = 91) |
P value |
|---|---|---|---|
| Demographics and laboratory | |||
| Men, n (%) | 61 (49.2) | 59 (64.8) | 0.023 |
| Age in years, median (IQR) | 41.5 (35–51) | 53 (45.5–61.5) | < 0.001 |
| Years of disease evolution, median (IQR) | 16 (10–23.5) | 20 (10–28) | 0.20 |
| BMI ≥ 30 kg/m2, n (%) | 26 (21.0) | 54 (59.3) | < 0.001 |
| Abnormal waist circumference*, n (%) | 71 (90.1) | 8 (90.1) | < 0.001 |
| Smokers, n (%) | 50 (40.3) | 23 (25.3) | 0.021 |
| HOMA-IR ≥ 2.15, n (%)† | 57 (47.5) | 83 (91.2) | < 0.001 |
| Diabetes mellitus, n (%) | 8 (6.5) | 23 (25.3) | < 0.001 |
| Cardiopathy, n (%) | 5 (4.0) | 10 (11.0) | 0.048 |
| Dyslipidemia, n (%) | 45 (36.3) | 57 (62.6) | < 0.001 |
| Metabolic syndrome, n (%) | 30 (24.2) | 54 (59.3) | < 0.001 |
| Psoriasis arthritis, n (%) | 18 (14.5) | 19 (20.9) | 0.22 |
| AST > 32 U/L, n (%) | 4 (3.2) | 14 (15.4) | 0.001 |
| ALT > 33 UL, n (%) | 14 (11.3) | 29 (31.9) | < 0.001 |
| GGT > 40 U/L, n (%) | 19 (15.3) | 31 (34.1) | 0.001 |
| Cholesterol > 200 mg/dL, n (%) | 33 (26.8) | 33 (36.3) | 0.13 |
| LDL-cholesterol > 100 mg/dL, n (%) | 90 (72.6) | 78 (85.7) | 0.021 |
| Triglycerides > 150 mg/dL, n (%) | 20 (16.1) | 40 (44.0) | < 0.001 |
| Albumin < 3.5 g/dL, n (%) | 2 (1.6) | 1 (1.1) | 0.99 |
| Hemoglobin < 11.5 g/dL, n (%) | 0 (0.0) | 1 (0.8) | 0.99 |
| White blood cells < 4.5 × 109/L, n (%) | 5 (4.0) | 1 (1.1) | 0.45 |
| Platelets < 150 × 109 /L, n (%) | 6 (4.8) | 1 (1.1) | 0.43 |
| ERS ≥ 16 mm, n (%) | 34 (28.1) | 33 (36.3) | 0.28 |
| Hs-CRP ≥ 0.1 mg/mL, n (%) | 82 (67.2) | 81 (89.0) | < 0.001 |
| Non-viable BT, n (%) | 17 (13.7) | 27 (29.7) | 0.004 |
| Severity scale | |||
| Psoriasis Area and Severity Index (PASI), median (IQR) | 1.5 (0–5) | 3.4 (1–8) | 0.008 |
| Body surface area (BSA), median (IQR) | 2 (0–6) | 4 (1–8) | 0.007 |
| Physician global assessment (PGA) (range 0–4), median (IQR) | 1 (0–2) | 2 (1–3) | 0.004 |
| Dermatology Life Quality Index (DLQI), median (IQR) | 2 (0–5) | 2 (1–3) | 0.74 |
| Itch, visual analog scale (range 0–10), median (IQR) | 2 (0–6) | 3 (0–6) | 0.52 |
| Pain, visual analog scale (range 0–10), median (IQR) | 0 (0–6) | 0 (0–6) | 0.23 |
AST aspartate aminotransferase, ALT alanine aminotransferase, BMI body mass index, BT bacterial translocation, ERS erythrocyte sedimentation rate, GGT g-glutamyl transferase, IQR interquartile range, hs-CPR high-sensitivity C-reactive-protein, HOMA-IR homeostatic model assessment of insulin resistance, LDL low-density lipoprotein.
*Abnormal waist circumference: women, ≥ 86 cm, ≥ 95 cm male.
†HOMA-IR available in 211 patients.